|
|
|
Strategic Partnering Opportunities
Concert Pharmaceuticals is applying its platform technology in deuterium chemistry to develop novel and differentiated small molecule patentable drugs. Concert has a broad pipeline of proprietary drug candidates in the areas of HIV, pain/spasticity, GI motility, infectious disease (MRSA, HCV, other) epilepsy, oncology, diabetic nephropathy, among others. Concert’s business strategy is to utilize collaborative pharmaceutical partnerships to drive these new chemical entities through development and commercialization to address unmet medical needs.
For further information please contact:
Greg Miller
Head of Business and Corporate Development
781.674.5227
BD@concertpharma.com |
E-Newsletter
Subscribe to Concert's quarterly business development newsletter to receive R&D updates, corporate news and more via e-mail.
|
Current Partners
GlaxoSmithKline - 2009
Corporate Materials
Upcoming Events
American Conference Institute's 16th Advanced Forum on:
Life Sciences Collaborative Agreements and M&A
New York, NY
February 27-28, 2012
BioNetwork East 2012
Miami, FL
March 5-7, 2012
2012 Business Development Biotech Conference
Boston, MA
April 16-17 2012
Allicense 2012
San Francisco, CA
May 1-2, 2012
[ back to top ]
|
|